Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2021)
Rani Therapeutics Holdings (RANI) posted quarterly Gains from Investment Securities of $85000.0 for Q3 2021, up 21.43% quarter-over-quarter from $70000.0 in Q2 2021.
Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Rani Therapeutics Holdings' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $85000.0 for Q3 2021.
- In Q3 2021, Gains from Investment Securities changed N/A year-over-year to $85000.0; the TTM figure through Sep 2022 stood at $85000.0 (down 92.19% YoY), while the FY2021 annual figure was $371000.0, up 488.89% from the prior year.
- Gains from Investment Securities for Q3 2021 stood at $85000.0, up from $70000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $718000.0 in Q4 2020, with the low at -$672000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 85,000.00 |
| Sep 30, 2021 | 85,000.00 |
| Jun 30, 2021 | 70,000.00 |
| Jun 30, 2021 | 70,000.00 |
| Mar 31, 2021 | 216,000.00 |
| Mar 31, 2021 | 216,000.00 |
| Dec 31, 2020 | 718,000.00 |
| Dec 31, 2020 | 718,000.00 |
| Jun 30, 2020 | -672,000.00 |
| Jun 30, 2020 | -672,000.00 |